drugset / Trial / NCT01373931

A Study of LY2216684 in Healthy Females

NCT01373931

Phase 1 Completed 20 enrolled Eli Lilly and Company
RandomizedCrossoverSingle-blindTreatment

Summary

This study involves a single dose of 18 milligrams (mg) LY2216684 taken as 1 or 2 tablets by mouth. The study will evaluate effect of LY2216684 on the pharmacokinetics of an oral contraceptive Ortho Cyclen®. This study will run approximately 93 days.

Timeline

Start
2011-06
Primary completion
2011-12
Completion
2011-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Norgestimate Small molecule 250 ug Oral
Subject edivoxetine Small molecule 18 mg Oral
Subject ethinyl estradiol Small molecule 35 ug Oral